Scotland's NICE dislikes GSK's Anoro

Scotland's version of NICE, the Scottish Medicines Consortium (SMC), says two COPD drugs are not worth the Scottish National Health Service's money.

Among the drugs Regulatory Focus found on the SMC's “not recommended” list were GlaxoSmithKline's Anoro (umeclidinium/vilantero) and Boehringer Ingelheim's Striverdi Respimat (olodaterol).

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.